Lafayette, R. Et Al. 2023. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. The Lancet , vol.402, no.10405 , 859-870.

Lafayette, R., Kristensen, J., Stone, A., Floege, J., Tesař, V., Trimarchi, H., ... Zhang, H.(2023). Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. The Lancet , vol.402, no.10405, 859-870.

Lafayette, Richard Et Al. "Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial," The Lancet , vol.402, no.10405, 859-870, 2023

Lafayette, Richard Et Al. "Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial." The Lancet , vol.402, no.10405, pp.859-870, 2023

Lafayette, R. Et Al. (2023) . "Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial." The Lancet , vol.402, no.10405, pp.859-870.

@article{article, author={Richard Lafayette Et Al. }, title={Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial}, journal={The Lancet}, year=2023, pages={859-870} }